Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 2, Pages 119–127
http://dx.doi.org/10.1155/2013/874212
Research Article

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

1National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia and Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia
2National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia
3University of Western Australia, School of Medicine and Pharmacology, and Sir Charles Gairdner Hospital, Department of Renal Medicine, Verdun Street, Nedlands, WA 6009, Australia
4School of Population Health, University of Western Australia and Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia
5Biostatistics Center, Massachusetts General Hospital, 50 Staniford Street, Suite 560, Boston, MA 02114-2521, USA
6National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia and Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia

Received 11 June 2013; Accepted 13 July 2013

Academic Editor: Irene Rebelo

Copyright © 2013 Jenette Creaney et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The MSLN gene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being investigated as biomarkers for the asbestos-related cancer malignant mesothelioma (MM). Pleural fluid biomarkers of MM can be elevated when serum levels remain normal. The aim of this study was to determine if this was true for MPF and to compare levels of mesothelin. Biomarker concentrations were compared in 66 MM patients, 39 patients with other malignancies, 37 with benign disease, 18 asbestos-exposed healthy individuals, and 53 patients with chronic kidney disease. In pleural effusions, MPF and soluble mesothelin concentrations were both significantly elevated in MM patients relative to controls. No significant difference between the area under the receiver operator curve (AUC) for MPF ( ) and mesothelin ( ) when distinguishing MM from all other causes of effusion was observed. MPF and mesothelin serum concentrations were highly correlated and of equivalent diagnostic accuracy with AUCs of and , respectively. Serum levels of both markers increased with decreasing kidney function. In conclusion, MPF is elevated in the pleural effusions of MM patients similar to that of mesothelin. Mesothelin and MPF convey equivalent diagnostic information for distinguishing MM from other diseases in pleural effusions as well as serum.